

Micturition disturbance in acute idiopathic autonomic neuropathy

R Sakakibara, T Uchiyama, M Asahina, et al.

J Neurol Neurosurg Psychiatry 2004 75: 287-291 doi: 10.1136/jnnp.2003.010298

Updated information and services can be found at: http://jnnp.bmj.com/content/75/2/287.full.html

	These include:
References	This article cites 21 articles, 7 of which can be accessed free at: http://jnnp.bmj.com/content/75/2/287.full.html#ref-list-1
Email alerting service	Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
Fopic collections	Articles on similar topics can be found in the following collections Incontinence (1015 articles)

Notes

To order reprints of this article go to: http://jnnp.bmj.com/cgi/reprintform

PAPER

Micturition disturbance in acute idiopathic autonomic neuropathy

R Sakakibara, T Uchiyama, M Asahina, A Suzuki, T Yamanishi, T Hattori

.....

J Neurol Neurosurg Psychiatry 2004;75:287-291

Objective: To define the nature of micturition disturbance in patients with acute idiopathic autonomic neuropathy (AIAN).

Methods: Micturitional symptoms were observed during hospital admissions and the in outpatient clinics in six patients with clinically definite AIAN (typical form in four, cholinergic variant in one, autonomic-sensory variant in one). Urodynamic studies included medium-fill water cystometry, external sphincter electromyography, and a bethanechol test.

See end of article for authors' affiliations

Correspondence to: Dr Ryuji Sakakibara, Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-Ku, Chiba 260-8670, Japan; sakaki@med.m. chiba-u.ac.jp

Received 26 March 2003 In revised form 6 May 2003 Accepted 7 May 2003 **Results:** Four patients had urinary retention and two had voiding difficulty as the initial presentation. Patients with retention became able to urinate within a week (two to seven days). The major symptoms at the time of urodynamic studies (three weeks to four months after disease onset in most cases) were voiding difficulty and nocturnal frequency. None had urinary incontinence. Complete recovery from the micturition disturbance took from three months to >18 years. The recovery period was shorter in a patient with cholinergic variant, and it was longer in two patients who had a longer duration of initial urinary retention. Micturition disturbance tended to improve earlier than orthostatic hypotension. The major urodynamic abnormalities were detrusor areflexia on voiding (5), denervation supersensitivity to bethanechol (3); low compliance detrusor (1); and impaired bladder sensation (2). None had neurogenic motor unit potentials of the external sphincter muscles.

Conclusions: In patients with AIAN, urinary retention and voiding difficulty are common initial presentations. The underlying mechanisms seem to be pre- and postganglionic cholinergic dysfunction with preservation of somatic sphincter function. The bladder problems tend to improve earlier than orthostatic hypotension.

cute idiopathic autonomic neuropathy (AIAN),12 or pure pandysautonomia, is a rare but distinct clinical entity first described by Young et al in 1969.3 4 The disorder involves both sympathetic and parasympathetic nervous systems, with an acute onset, a monophasic course, and partial recovery with relative preservation of sensory function.⁵ Somatic motor function is almost completely preserved. The site of lesions is the pre- and postganglionic autonomic fibres,¹⁵ and the disorder is thought to have an autoimmune aetiology similar to the Guillain-Barré syndrome.⁶⁷ Variant forms may also occur,⁵ in which sensory fibres are involved⁸ ⁹ or cholinergic autonomic fibres alone are affected.10 The most common presenting symptoms of AIAN are orthostatic hypotension (postural dizziness, syncope), gastrointestinal (nausea, vomiting, diarrhoea, constipation, intestinal pseudo-obstruction), and sudomotor (failure to sweat, causing heat intolerance and flushing).⁵ Disturbances of micturition are known to occur in this disorder, and most patients suffer from voiding difficulty and retention, which often requires an indwelling urinary catheter.1-4 6 8-10 However, few studies have attempted to follow up the bladder symptoms and investigate the underlying mechanism, though Kirby et al investigated two patients with this condition.¹¹ In this paper we outline our findings relating to the micturition histories in six patients with AIAN, and describe the urodynamic studies that were done.

METHODS

Patients

This was a retrospective study in which we reviewed the records of six patients with AIAN, all of whom satisfied the inclusion and exclusion diagnostic criteria.^{1 2 5} Two were male

and four were female, median age of onset 30 years (range 9 to 46). All the patients experienced acute exacerbations of autonomic abnormalities during the first two to four weeks, but motor function was almost completely preserved. On the basis of the neurological and neurophysiological findings and the autonomic function tests (done within a month of onset except in two cases) (table 1),^{7 12-15} four patients (cases 2, 3, 4, and 5) were considered to have the typical form of the disease and the other two to have variant forms (case 1, acute cholinergic autonomic neuropathy; case 6, acute autonomic sensory neuropathy).

Procedures

Micturitional and other autonomic symptoms were observed during hospital admission and in the follow up outpatient clinic. The follow up period was six months in one patient and more than four years (4 to 18) in five. Micturition status of the patients with an indwelling urinary catheter was evaluated at least one week after removal of the catheter. Patients with urinary symptoms did not have urinary tract infection. One patient under 10 years of age (case 2) did not have a recent history of enuresis. In four patients, urodynamic studies were done three weeks to four months after the onset of disease, while in the remaining two patients, urodynamic and autonomic function tests were done four and 18 years after the onset of disease. In one patient (case 3) the urodynamic studies were repeated. None of the male patients studied had prostatic hypertrophy on abdominal ultrasonography. Informed consent was obtained from all the patients before the urodynamic studies were done.

In the patients, we also undertook peripheral nerve examinations including nerve conduction studies and sural nerve biopsy.

	Patient							
Variable	1 (KA)	2 (TO)	3 (TO)	4 (MM)	5 (CK)	6 (ET)		
Age of onset (years)/sex Initial symptoms	46/M Anhidrosis, urinary retention	9/M Diarrhoea, vomiting, urinary retention	23/M Abdominal distension, vomiting	34/M Syncope	37/F Vomiting, urinary retention	28/F Abdominal pain, diarrhoea		
Clinical form	Cholinergic variant	Typical form	Typical form	Typical form	Typical form	Autonomic-sensor variant		
Autonomic signs and symptoms								
Orthostatic syncope	-	+	+	+	+	+		
Pupillary abnormality	-	Tonic pupil	Tonic pupil	Tonic pupil	-	-		
Anhidrosis	+	+	+	+	+	+		
Paroxysmal coughing	+	-	+	+	+	-		
Constipation/intestinal pseudo-obstruction	+	+	+	+	+	+		
Erectile dysfunction	+	+ (afterwards)	+	+				
Urinary dysfunction	Retention (3 days), voiding difficulty	Retention (7days), voiding difficulty	Voiding difficulty, nocturia	Voiding difficulty	Retention (2 days), voiding difficulty	Retention (7 days) voiding difficulty		
Deep tendon reflexes	Normal	Absent	Absent	Absent	Decreased	Absent		
Sensory signs and symptoms								
Fingling sensation/numbness Decrease in pain, touch Decrease in position,	+ (hands, feet) -	-	– + (hands)	+ (hands) + (hands)	+ (generalised) -	+ (generalised) + (generalised)		
vibration/sensory ataxia, Romberg sign	-	-	-	-	-	+ (generalised)		
Autonomic function tests Cardiovascular function		<18 years later>				<4 years later>		
Systolic pressure fall (mm Hg) in head up tilt (70°, 10 min) (normal <20) Supine plasma noradrenaline	Normal	Normal*	50 (30°)	76	18 (30°)	58		
(NA) (pg/ml) (normal >100) Supersensitivity to NA infusion	291	np	40	50	20	30		
(0.'1 mg/kg, 5 min) Sudomotor function	Np	np	+	+	+	+		
Thermal/sympathetic sweat response Pupillary responses Supersensitivity to 1.25% NA	Absent	Absent	Absent	np	Absent	Absent		
instillation (60 min) Supersensitivity to 0.125% pilocarpine	Normal	+	+	Normal	+	+		
instillation (30 min)	Normal	+	+	+	+	np		
Peripheral nerve examination Nerve conduction studies								
Nedian, ulnar, tibial, sural nerves Sural nerve biopsy Light microscopy: decreased	Normal	Normal	Normal	Normal	Normal	Decreased SNAP		
ibre density	+	np	+	+	+	np		
compared with control)	Np	np	Small myelinated 7%, unmyelinated 3%		Small myelinated 26%, unmyelinated 9%	np		

Urodynamic studies

The urodynamic studies consisted of uroflowmetry, measurement of residual urine, urethral pressure profilometry, medium-fill (50 ml/min) water cystometry, and external sphincter electromyography (EMG) with a urodynamic computer (Urovision; Lifetech, Houston, Texas, USA) and an EMG computer (Neuropack Σ ; Nihon Kohden, Tokyo, Japan). Uroflow curves were evaluated according to Siroky's nomogram.¹⁶ The normal ranges of urodynamic variables were: residual urine volume under 30 ml; maximum urethral closure pressure more than 41 cm H₂O and less than 82 cm H₂O; first sensation at the bladder volume more than 100 ml but less than 300 ml; and bladder capacity more than 200 ml but less than 600 ml. Increased first sensation and/or bladder capacity indicates impaired bladder sensation.

Analysis of sphincter motor unit potentials was done in four patients using a concentric needle electrode. According

to the criteria proposed by Palace *et al*,¹⁷ neurogenic sphincter EMG was diagnosed when either of the following abnormalities was present: average duration of motor unit potentials >10 ms; >20% of motor unit potentials with a duration of >10 ms. A bethanechol test was done in five patients. After an infusion of 100 ml of water, 2.5 mg of bethanechol chloride was injected subcutaneously and detrusor pressure was measured for 30 minutes. A detrusor pressure increase of >15 mm H₂O during the test is considered high.¹⁸ The methods and definitions used for the urodynamic studies conformed to the standards proposed by the International Continence Society.¹⁹

RESULTS

Initial presentation

All the patients had urinary dysfunction at the onset of their disease (table 1). Four patients had transient urinary

retention which required urinary catheterisation; the other two had voiding difficulty with or without nocturnal urinary frequency. All patients with urinary retention became able to urinate within a week (two to seven days), including those who underwent steroid pulse treatment. While three patients needed midodrine or L-threoDOPS for the treatment of orthostatic hypotension, none needed drug treatment for the micturition disturbance.

With respect to other autonomic disturbances, all the patients except one (case 1, cholinergic variant) had frequent episodes of orthostatic dizziness and syncope. All patients had intestinal pseudo-obstruction or severe constipation, and four also had vomiting, abdominal distension, and pain. All patients had anhidrosis, four had intractable paroxysmal coughing, three had tonic pupils, and all four male patients had erectile dysfunction (which developed later in a young patient).

Urodynamic studies

When the urodynamic studies were done, all patients still had moderate micturition disturbance (table 2). The major symptoms were voiding difficulty and nocturnal urinary frequency. However, none of the patients developed urinary incontinence or recurrent urinary retention.

Post-void residual urine volume was measured in all the patients. Residual urine of more than 30 ml was noted in three (median volume, 50 ml) but none had a residual volume of more than 100 ml. Water cystometry was done in all cases. Bladder volume at first sensation, bladder capacity, or both were decreased in one patient and increased in two: one patient had increased first sensation (340 ml); another had increased bladder capacity (>750 ml; water infusion stopped to avoid overdistension). During bladder filling, one patient showed a low compliance detrusor. During voiding, five patients had detrusor areflexia.

The bethanechol test was done in five patients, three of whom showed supersensitivity of the bladder. External sphincter EMG showed unrelaxing sphincter on voiding in one patient. Analysis of sphincter motor unit potentials was done in four patients, and none had neurogenic changes in the sphincter motor unit potentials.

In addition to the above urodynamic abnormalities, one patient (case 2) with diurnal frequency had polyuria (>2200 ml/day) because of an excessive water intake, as he had heat intolerance caused by generalised anhidrosis.

variantvariantvariantvariantlineral barse disase onset and uradynamic studies4 Months18 Years2 Months4 Months3 Weeks4 YearsMicturition symptoms(at the time of uradynamic studies)++Nactural frequency++Urgency+++IncontinenceIncontinenceHeatmin-+//-++//-++Uradynamic studies <th></th> <th colspan="8">Patient</th>		Patient							
variantvariantvariantvariantIntervol between disease onset and uradynamic studies4 Months18 Years2 Months4 Months3 Weeks4 YearsMicturition symptoms(at the time of uradynamic studies)+++Nactural frequency+++Urgency+++Urgency++IncontinenceHestincy/ prolongation-+//-++//-+-Retention-+//-+Post-void residual urine (ml) (normal<30)505060-Nacimum urathral closure pressure (nm+20) (14.0romal<520)>100np336360np18 Ideder capozity (ml) (200<-normal<540)350250500350350>75020 Envosor hypereflexia during filling Detrusor hypereflexia during filling (2.5 mg. 30 min)10 Envosor hypereflexia during filling (2.5 mg. 30 min)	Variable	1 (KA)	2 (TO)	3 (TO)	4 (MM)	5 (CK)	6 (ET)		
uradynamic studies4 Months18 Years2 Months4 Months3 Weeks4 YearsMicturition symptoms(at the time of uradynamic studies)+-+-++Nacturnal frequency++Urgency++IncontinenceHestincy/prolongation-+/-++RetentionUradynamic studiesPetravid residual urine (ml)505060 <td></td> <td></td> <td>Typical form</td> <td>Typical form</td> <td>Typical form</td> <td>Typical form</td> <td>Autonomic-sensory variant</td>			Typical form	Typical form	Typical form	Typical form	Autonomic-sensory variant		
Nocturnal frequency+-+-++Durnal frequency-+*++Incontinence++IncontinenceRetention-+/-++/-+-RetentionDecreased uniary flownp+npnpnp+Post-void residual urine (ml)505060-Inormal <s20)< td="">505060Maximum urethral closure pressure5060[cm H_2O] (41 < normal<82)</s20)<>	urodynamic studies	4 Months	18 Years	2 Months	4 Months	3 Weeks	4 Years		
Nocturnal frequency+-+-++Durnal frequency-+*++Incontinence++IncontinenceRetention-+/-++/-+-RetentionDecreased uniary flownp+npnpnp+Post-void residual urine (ml)505060-Inormal <s20)< td="">505060Maximum urethral closure pressure5060[cm H_2O] (41 < normal<82)</s20)<>	Micturition symptoms(at the time of urod	ynamic studies)							
Diumal frequency-+*++Urgency <t< td=""><td>Nocturnal frequency</td><td>+</td><td>_</td><td>+</td><td>-</td><td>+</td><td>+</td></t<>	Nocturnal frequency	+	_	+	-	+	+		
Urgan+++Incontinence <td></td> <td></td> <td>+*</td> <td>_</td> <td>_</td> <td>_</td> <td></td>			+*	_	_	_			
IncontinenceDecreaced urinary flownpnp1np33336360np000 <td></td> <td></td> <td></td> <td>_</td> <td>_</td> <td></td> <td></td>				_	_				
Hesitancy/prolongation Retention-++/-+/-+RetentionUrodynamic studies Decreased urine (ml) (normal<30)			-		-				
Retention<			-,		-,		-		
Uradynamic studies Decreased urinary flownpnp+npnpnp+Post-viol residual urine (ml) (normal<30)		-	+/-	+	+/-	+	-		
Decréased urinary flow Post-void residual urine (ml) (normal-30)np+npnpnp+Post-void residual urine (ml) (normal-30)505060-Maximum urethral closure pressure (cm H2O) (41-conrmal-820)>100np336360npFirst sensation (ml) (100-normal-820)24080340200250160Bladder capacity (ml) (200 <normal-600)< td="">350250500350350>750Detrusor hyperreflexia during filling Detrusor or hyperreflexia on voiding (25 mg 30 min)Unrelaxing sphincter on voiding of the external sphincterNeurogenic motor unit potentials of the external sphincterTreatmentSteroid pulse therapy, oral prednisolone klordore grotomine for CH, sildenafil for CD,Steroid pulse therapy, oral prednisolone, complete recovery (ding difficulty (disappeared (4 months), complete recovery (6 months)Noturia sidenafil withdrawnSteroid pulse therapy col presisted (18 years)Viniary frequency, voiding difficulty disappeared (6 months), OH persisted (12 years)Uniary frequency, voiding difficulty graduallyUniary frequency, voiding difficulty gradually graduallyUniary frequency, voiding difficulty gradually graduallyUniary frequenc</normal-600)<>	Retention	-	-	-	-	-	-		
Post-void residual urine (ml) (normal-30) 50 - - 50 60 - Maximum urethral closure pressure (cm H ₂ O) (41 <-normal<82)	Urodynamic studies								
Post-void residual urine (ml) (normal<30)	Decreased urinary flow	np	+	np	np	np	+		
(normal<30)505060-Maximum urethral closure pressure (cm H2O) (41 -normal<82)	Post-void residual urine (ml)			1	1				
Maximum urethral closure pressure (am H ₂ O) (41 <normal<82)< th="">>100np336360np[adder capacity (ml)24080340200250160Bladder capacity (ml)350250500350350>750[200<normal<600)< td="">350250500350350>750Detrusor hyperreflexia during fillingLow compliance detrusor during fillingDetrusor hyperreflexia on voiding+/-+-++/-+Supersensitivity to bethanechol injection-np++-+(2.5 mg, 30 min)-np+/Verogenic motor unit potentials-np++of the external sphincternpnpTreatmentSteroid pulseSteroid pulse therapy, oral prednisolone, dihydroergotamine for OH, sildenafil for EDCorlLativeMidodrine for OHCourseNocturiaDiurnal frequency (4 months), complete (6 months)Diurnal frequency (18 years)Viainay frequency, ording difficulty disappeared (18 years)Urinary frequency, viaing difficulty disappeared (12 years)Urinary frequency, viaing difficulty disappeared (12 years)Urinary frequency, viaing difficulty disappeared (12 years)Urinary frequency, viaing difficulty disappeared (12 years)Urinary frequency, viaing dif</normal<600)<></normal<82)<>		50	_	_	50	60	_		
(cm H2O) (41 < normal < 82)>100np336360npFirst sensation (ml) (100 < normal < 300)		50			50	00			
First sensation (ml) (100 <normal<300)< td=""> 240 80 340 200 250 160 Bladder capacity (ml) (200-normal<500)</normal<300)<>		> 100		22	(0	10			
Bladder capacity (ml) 350 250 500 350 350 >750 Detrusor hyperreflexia during filling -									
(200 <normal<600)< td=""> 350 250 500 350 350 >750 Detrusor hyperreflexia during filling -</normal<600)<>		240	80	340	200	250	160		
Detrusor hyperreflexia during filling Low compliance detrusor during filling Detrusor areflexia on voiding Usupersensitivity to bethanechol injection (2.5 mg, 30 min) - <		350	250	500	350	350	>750		
Low compliance detrusor during filling Detrusor areflexia on voiding Supersensitivity to bethanechol injection (2.5 mg, 30 min)<									
Detrusor areflexia on voiding+/-+-++/-+Supersensitivity to bethanechol injection-np++-+Supersensitivity to bethanechol injection-np++-+Unrelaxing sphincter on voiding-+/Neurogenic motor unit potentials-+/of the external sphincternpnpTreatmentSteroid pulse therapy, oral prednisoloneSteroid pulse therapy, oral prednisolone, 									
Supersensitivity to bethanechol injection (2.5 mg, 30 min)-np++-+Unrelaxing sphincter on voiding Neurogenic motor unit potentials of the external sphincter <i>Neurogenic motor unit potentials</i> of the external sphincter <i>Treatment</i> Steroid pulse therapy, oral prednisolone prednisoloneSteroid pulse therapy, oral prednisolone, dihydroergotamine for OH, sildenafil for EDOral prednisoloneL-threoDOPS, midodrine for OHLaxative for constipationMidodrine for OHCourseNocturia disappeared (4 months), complete recovery (6 months)Diurnal frequency persisted (18 years), OH changed to POTS, Sildenafil withdrawn because of POTS (18 years)Urinary frequency, voiding difficulty utrinary frequency, tiasppeared (3 months), OH upersisted (3 years)Urinary frequency, voiding difficulty persisted (3 years)Urinary frequency, voiding difficulty persisted (12 years)Urinary frequency, voiding difficulty disappeared (3 months); OH lessened but persistedUrinary frequency, voiding difficulty disappeared (3 months); OH persistedUrinary frequency, voiding difficulty disappeared (3 months); OH lessened bu		- ,	-	-		- ,	-		
(2.5 mg, 30 min) - np + + - + Unrelaxing sphincter on voiding Neurogenic motor unit potentials of the external sphincter - +//- - - - - Treatment Steroid pulse therapy, oral prednisolone Steroid pulse therapy, oral prednisolone, disydroergotamine for OH, sildenafil for ED Steroid pulse therapy, oral prednisolone, disydroergotamine for OH, sildenafil Oral prednisolone L-threoDOPS, midodrine for OH Laxative for constipation Midodrine for OH Course Nocturia disappeared (4 months), complete recovery (6 months) Diurnal frequency persisted (18 years) Urinary frequency, oH changed to POTS, sildenafil withdrawn because of POTS (18 years) Urinary frequency, persisted (3 years) Voiding difficulty disappeared (12 years) Urinary frequency, requency, tisappeared (12 years) Urinary frequency, persisted (3 years) Voiding difficulty persisted (3 years) Urinary frequency, tisappeared (3 months), OH		+/-	+	-	+	+/-	+		
Unrelaxing sphincter on voiding Neurogenic motor unit potentials of the external sphincter - +/- - </td <td>Supersensitivity to bethanechol injection</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Supersensitivity to bethanechol injection								
Unrelaxing sphincter on voiding Neurogenic motor unit potentials of the external sphincter - +/- - </td <td>(2.5 mg, 30 min)</td> <td>-</td> <td>np</td> <td>+</td> <td>+</td> <td>-</td> <td>+</td>	(2.5 mg, 30 min)	-	np	+	+	-	+		
Neurogenic motor unit potentials of the external sphincter - - np np np - - Treatment Steroid pulse therapy, oral prednisolone Steroid pulse therapy, oral prednisolone, dihydroergotamine for OH, sildenafil for ED Steroid pulse therapy, oral prednisolone, dihydroergotamine for OH, sildenafil for ED Oral prednisolone L-threoDOPS, midodrine for OH Laxative for constipation Midodrine for OH Course Nocturia disappeared (4 months), complete recovery (6 months) Diurnal frequency persisted (18 years), OH changed to POTS, Sildenafil withdrawn because of POTS (18 years) Urinary frequency, voiding difficulty (2 years) Voiding difficulty disappeared (3 months), OH persisted Urinary frequency, voiding difficulty disappeared (12 years) Uri	Unrelaxing sphincter on voiding	-		-	-	-	-		
of the external sphincter - - np np np - - - Treatment Steroid pulse therapy, oral prednisolone Steroid pulse therapy, oral prednisolone, dihydroergotamine for OH, sildenafil for ED Steroid pulse therapy, oral prednisolone Oral prednisolone L-threoDOPS, midodrine for OH Laxative for constipation Midodrine for OH Course Nocturia disappeared (4 months), complete recovery (6 months) Diurnal frequency persisted (18 years), OH changed to POTS, Sildenafil withdrawn because of POTS (18 years) Urinary frequency, voiding difficulty (2 years) Voiding difficulty disappeared (3 months), OH persisted Urinary frequency, voiding difficulty disappeared (12 years) Urinary frequency, voiding difficulty disappeared (12 years) Urinary frequency, voiding difficulty disappeared (3 months); OH persisted Urinary frequency, voiding difficulty disappeared (12 years) Urinary frequency, voiding difficulty disappeared (3 months); OH									
TreatmentSteroid pulse therapy, oral prednisoloneSteroid pulse therapy, oral prednisolone, dihydroergotamine for OH, sildenafil for EDOral prednisoloneL-threoDOPS, midodrine for OHLaxative for constipationMidodrine for OHCourseNocturia disappeared (4 months), complete recovery (6 months)Diurnal frequency persisted (18 years), OH changed to POTS (18 years)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (12 years)Urinary frequency, recovery (3 months); OH lessened but persisted but persisted but persisted butUrinary frequency, voiding difficulty disappeared (3 months); OH lessened but persisted but persisted but persisted but persisted but		_	_	20	nn	_	_		
therapy, oral prednisoloneoral prednisolone, dihydroergotamine for OH, sildenafil for EDprednisolonemidodrine for OHfor constipationfor OHCourseNocturia disappeared (4 months), complete (6 months)Diurnal frequency persisted (18 years), OH changed to POTS, (6 months)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, requency, voiding difficulty (12 years)Urinary frequency, (12 years)Urinary frequency, voiding difficulty (12				np	ΠÞ				
therapy, oral prednisoloneoral prednisolone, dihydroergotamine for OH, sildenafil for EDprednisolonemidodrine for OHfor constipationfor OHCourseNocturia disappeared (4 months), complete recovery (6 months)Diurnal frequency persisted (18 years), OH changed to POTS, Sildenafil withdrawn (18 years)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (12 years)Urinary frequency, requency, voiding difficulty disappeared (12 years)Urinary frequency, requency, voiding difficulty (18 years)Urinary frequency, voiding difficulty (18 years)Urinary frequency, voiding difficulty (12 years)Urinary frequency, requency, voiding difficulty (12 years)Urinary frequency, voiding difficulty (12 years), (12 years)Urinary frequency, voiding difficulty (12 years)Urinary frequency, voiding difficulty (12 years), (12 years)Urinary frequency, voiding difficulty (12 years), (12 years)Urinary frequency, voiding difficulty (12 years), (12 years), (12 years)Urinary frequency, voiding difficulty (12 years), (12 years),Urinary frequency, voiding difficul	Treatment	Steroid pulse	Steroid pulse therapy,	Oral	L-threoDOPS,	Laxative	Midodrine		
prednisolonedihydroergotamine for OH, sildenafil for EDOHCourseNocturia disappeared (4 months), completeDiurnal frequency persisted (18 years), OH changed to POTS, Sildenafil withdrawn tecovery (6 months)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (6 months), normal UDS (2 years); OH persisted (3 years)Urinary frequency, voiding difficulty disappeared (6 months), OH persisted (12 years)Urinary frequency, voiding difficulty disappeared (6 months), OH persisted (12 years)Urinary frequency, disappeared (6 months), OH persisted (12 years)Urinary frequency, requency, voiding difficulty (12 years)Urinary frequency, requency, voiding difficulty (4 years) gradually		therapy oral	oral prednisolone	prednisolone	midodrine for	for constinution	for OH		
For OH, sildenafil for ED For OH, sildenafil for ED Course Nocturia Diurnal frequency Urinary frequency, voiding difficulty Urinary Urinary Urinary frequency disappeared persisted (18 years), voiding difficulty disappeared frequency, OH persisted (4 months), OH changed to POTS, disappeared (6 months), OH voiding difficulty voiding difficulty recovery because of POTS UDS (2 years); OH persisted disappeared (6 months) (18 years) persisted (3 years) (12 years) (3 months); OH lessened but persisted but persisted persisted but				produitoriorio		ior company			
Course Nocturia disappeared (4 months), complete Diurnal frequency persisted (18 years), Sildenafil withdrawn (6 months) Urinary frequency, voiding difficulty disappeared (6 months), OH Urinary frequency, (6 months), OH Urinary frequency, (6 months), OH Urinary persisted (18 years), voiding difficulty Urinary disappeared (6 months), OH Urinary frequency, (6 months), OH Urinary persisted (18 years) Course Nocturia disappeared (6 months) Diurnal frequency persisted (18 years) Urinary frequency, voiding difficulty Urinary frequency, disappeared (6 months), OH Urinary frequency, voiding difficulty Urinary frequency, frequency, (6 months), OH OH persisted (6 months) 0H changed to POTS, sildenafil withdrawn (6 months) UDS (2 years); OH persisted (3 years) Issepeared (3 months); OH lessened but persisted Issepeared but persisted		preditisoione			OII				
CourseNocturia disappeared (4 months), completeDiurnal frequency persisted (18 years), OH changed to POTS, sidenafil withdrawn (6 months), normalUrinary frequency, voiding difficulty (6 months), NOH ussisted (18 years), voiding difficultyUrinary frequency, voiding difficulty (6 months), NOH ussisted (18 years), voiding difficultyUrinary frequency, voiding difficulty (4 years) graduallyCourseOH changed to POTS, sildenafil withdrawn (6 months), normal UDS (2 years); OH persisted (3 years)(6 months), OH (12 years)voiding difficulty (4 years) gradually (3 months); OH lessened but persisted but persisted									
disappeared persisted (18 years), voiding difficulty disappeared frequency, OH persisted (4 months), OH changed to POTS, disappeared (6 months), OH voiding difficulty (4 years) complete Sildenafil withdrawn (6 months), normal lessened but gradually recovery because of POTS UDS (2 years); OH persisted disappeared (6 months) (18 years) persisted (3 years) (12 years) (3 months); OH lessened but persisted			for ED						
disappeared persisted (18 years), voiding difficulty disappeared frequency, OH persisted (4 months), OH changed to POTS, disappeared (6 months), OH voiding difficulty (4 years) complete Sildenafil withdrawn (6 months), normal lessened but gradually recovery because of POTS UDS (2 years); OH persisted disappeared (6 months) (18 years) persisted (3 years) (12 years) (3 months); OH lessened but persisted	Course	Nocturia	Diurnal frequency	Urinary frequency,	Voiding difficulty	Urinary	Urinary frequency		
(4 months), OH changed to POTS, disappeared (6 months), OH voiding difficulty (4 years) complete Sildenafil withdrawn (6 months), normal lessened but gradually recovery because of POTS UDS (2 years); OH persisted disappeared (6 months) (18 years) persisted (3 years) (12 years) (3 months); OH lessened but persisted		disappeared	persisted (18 years)			frequency			
complete Sildenafil withdrawn (6 months), normal lessened but gradually recovery because of POTS UDS (2 years); CH persisted disappeared (6 months) (18 years) persisted (3 years) (12 years) (3 months); CH lessened but persisted									
recovery because of POTS UDS (2 years); OH persisted disappeared (6 months) (18 years) persisted (3 years) (12 years) (3 months); OH lessened but persisted							(4 years)		
(6 months) (18 years) persisted (3 years) (12 years) (3 months); OH lessened but persisted									
lessened but persisted									
persisted		(6 months)	(18 years)	persisted (3 years)	(12 years)				
						lessened but			
						persisted			
LI / vears)						(17 years)			

Follow up

The period for complete recovery of the micturition disturbance ranged widely, from three months to more than 18 years. There was no apparent correlation between the recovery period and the sex of the patient or the age of onset. However, the recovery period was shorter (four months) in one patient with acute cholinergic autonomic neuropathy (without orthostatic hypotension), and it was longer (more than four years) in two patients in whom the duration of initial urinary retention was longer (seven days). Comparing the recovery periods for the micturition disturbance and orthostatic hypotension, the micturition disturbance tended to improve earlier than the orthostatic hypotension (three months to four years for micturition disturbance, except in one cases, where it lasted for 18 years; three years to 18 years for orthostatic hypotension).

DISCUSSION

Although AIAN is rare,⁵ micturition disturbance is well recognised in this disorder. In the present study, all six patients showed micturition disturbance as the initial presentation, four of whom required urinary catheterisation for relief of urinary retention. The other two patients had voiding difficulty with or without nocturia. The high incidence of micturition disturbances reported here is in accordance with previous series of patients with AIAN,^{1-4 6 11} including the variant forms (acute autonomic-sensory neuropathy^{8 9} and acute cholinergic neuropathy^{10 11 20}). All of our patients with urinary retention became able to urinate within a week (two to seven days). However, when the urodynamic studies were done (three weeks to four months in the majority), all patients still had moderate micturition disturbance. The major symptoms were voiding difficulty and nocturnal urinary frequency. However, none developed urinary incontinence, post-void residuals of more than 100 ml, or recurrent urinary retention. In our patients, the period for complete recovery of micturition disturbance ranged widely from three months to more than 18 years. The recovery period was shorter (four months) in one patient with acute cholinergic autonomic neuropathy (without orthostatic hypotension), and it was longer (more than four years) in the two patients who had a longer duration (seven days) of initial urinary retention. Thus the severity of micturition disturbance at the initial presentation may predict the duration of the subsequent disturbance. Though severe micturition disturbance appears to occur as often as orthostatic hypotension, it tended to resolve earlier in our series (within three months to four years, with one case lasting 18 years, versus three 3 years to 18 years).

Although we have not done urodynamic studies during the initial retention period, "atonic bladder" was described in the original report by Young et al.3 4 We carried out our urodynamic studies three weeks to four months after the onset of disease except in two cases. Our major findings included detrusor areflexia on voiding in five patients, a positive bethanechol test in three, low compliance detrusor in one, and disturbed bladder sensation in two. Our findings support the earlier study by Kirby *et al*,¹¹ who described two patients with AIAN: one cholinergic variant (case 1; an 11 year old girl) and one typical form (case 2; a 53 year old woman). Both initially had urinary retention. In case 1, the retention resolved a month later, but she still had voiding difficulty for the following 15 years. In case 2, urinary retention persisted for four years before urodynamic studies were done, and these showed detrusor areflexia on voiding. Detrusor areflexia is a common feature in diabetic polyneuropathy,²¹ and it also occurs in severely affected cases of Guillain-Barré syndrome.⁷²² It indicates a postganglionic type

of pelvic (parasympathetic cholinergic) nerve dysfunction which is the major cause of evacuation disorders.²³

Three of our patients showed supersensitivity to a minimal amount of bethanechol. Supersensitivity to carbachol was also noted by Kirby *et al* in both their cases.¹¹ These findings most probably reflect denervation of the detrusor smooth muscles owing to the postganglionic pelvic nerve lesion,¹⁸ which has been confirmed by a reduction of acetylcholines-terase containing nerves in biopsies of the bladder muscle.¹¹ One of our patients showed a low compliance detrusor, which was also noted in Kirby's case 2.¹¹ A low compliance detrusor commonly occurs in spinal conus or cauda equina lesions^{24 25} and indicates a preganglionic type of pelvic nerve dysfunction.²³

There was a discrepancy in that impaired bladder sensation was noted in two of our patients but in none of Kirby's cases. Impaired bladder sensation indicates disturbance of afferent fibres from the bladder wall, although it might also be a result of potential overdistension injury during the initial retention period. Analysis of the sphincter motor unit potentials showed that none had denervation potentials, which is in agreement with the earlier study.¹¹ The external sphincter did not relax completely during voiding in only one of the five patients who had detrusor areflexia, suggesting mild sphincter dysfunction. Nerve conduction studies and sural nerve biopsy in the present study showed severe loss of small myelinated and unmyelinated nerve fibres, with preservation of somatic motor nerves, which is consistent with previous reports.¹⁵ Thus the external striated sphincter muscles (innervated by somatic pudendal nerves) tend to be preserved in this disorder.

Conclusions

In our patients with acute idiopathic autonomic neuropathy, urinary retention and voiding difficulty were common initial presentations. The underlying mechanisms seem to be preand postganglionic cholinergic dysfunction with preservation of somatic sphincter function. The problems tend to resolve earlier than orthostatic hypotension.

Authors' affiliations

R Sakakibara, T Uchiyama, M Asahina, A Suzuki, T Hattori,

Department of Neurology, Chiba University School of Medicine, Chiba, Japan

T Yamanishi, Department of Urology, Dokkyo Medical College, Tochigi, Japan

Competing interests: none declared

REFERENCES

- Suarez GA, Fealey RD, Camillei M, et al. Idiopathic autonomic neuropathy; clinical neurophysiologic and follow-up studies on 27 patients. *Neurology* 1994;44:1675–82.
- 2 Low PA, Dyck PJ, Lambert EH, et al. Acute panautonomic neuropathy. Ann Neurol 1983;13:412–17.
- 3 Young R, Asbury AK, Adams RD, et al. Pure pandysautonomia with recovery. Trans Am Neurol Assoc 1969;**94**:355–7.
- 4 Young R, Asbury AK, Corbett JL, et al. Pure pandysautonomia with recovery; description and discussion of diagnostic criteria. Brain 1975;98:613–36.
- 5 Low PA, McLeod JG. Autonomic neuropathies. In: Low PA, ed. Clinical autonomic disorders, 2nd ed. Philadelphia: Lippincott-Raven, 1997:463–86.
- 6 Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997;62:529–31.
- 7 Sakakibara R, Hattori T, Kuwabara S, et al. Micturitional disturbance in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;63:649–53.
- Colar RV, Snead OC, Oh SJ, et al. Acute autonomic and sensory neuropathy. Ann Neurol 1980;8:441–4.
- 9 Pavesi G, Gemignani F, Macaluso GM, et al. Acute sensory and autonomic neuropathy; possible association with Coxsackie B virus infection. J Neurol Neurosurg Psychiatry 1992;55:613–15.
- Harik SI, Ghandour MH, Farah FS, et al. Postganglionic cholinergic dysautonomia. Ann Neurol 1977;1:393–6.

Downloaded from jnnp.bmj.com on April 25, 2010 - Published by group.bmj.com

Micturition disturbance in acute autonomic neuropathy

- Kirby R, Fowler CJ, Gosling JA, et al. Bladder dysfunction in distal autonomic neuropathy of acute onset. J Neurol Neurosurg Psychiatry 1985;48:762-7.
- neuropathy of acute onset. J Neurol Neurosurg Psychiatry 1985;48:/62-7.
 Kita K, Hirayama K, Ito N. Acute idiopathic pandysautonomia; report of four cases. Auton Nerv Syst 1983;20:67-75.
- 13 Kita K, Hirayama K. A morphological approach to autonomic function; quantitative electronmicroscopic studies on unmyelinated fibers from sural nerve biopsies in patients with systemic dysautonomia. *Auton Nerv Syst* 1986;23:266–75.
- 14 Asahina M, Kuwabara S, Suzuki A, et al. Autonomic function in demyelinating and axonal subtypes of Guillain-Barré syndrome. Acta Neurol Scand 2002;105:44–50.
- 15 Cross SA. Autonomic disorders of the pupil, ciliary body, and lachrymal apparatus. In: Low PA, ed. *Clinical autonomic disorders*, 2nd ed. Philadelphia: Lippincott-Raven, 1997:441–54.
- Philadelphia: Lippincott-Raven, 1997:441–54.
 Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram, 2. Clinical correlation, *J Urol* 1980;123:208–10.
- 17 Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. *Muscle Nerve* 1997;20:1396–403.

- 18 Lapides J, Friend CR, Ajemian EP, et al. Denervation supersensibility as a test for neurogenic bladder. Surg Gyn Obst 1962;114:241-4.
- 19 Abrams P, Blaivas JG, Stanton SL, et al. The standardization of terminology of lower urinary tract function; produced by the International Continence Society Committee on Standardization of Terminology. Neurourol Urodynam 1988;7:403–26.
- Takayama H, Kazahaya Y, Kashihara N, et al. A case of post-ganglionic cholinergic dysautonomia. J Neurol Neurosurg Psychiatry 1987;50:915–18.
 Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic
- 21 Kapian SA, Te AE, Blaivas JC. Urodynamic findings in patients with diabetic cystopathy. J Urol 1995;153:342–4.
- 22 Wheeler JS, Siroky MB, Pavlakis A, et al. The urological aspects of the Guillain-Barré syndrome. J Urol 1984;131:917–19.
- 23 Blaivas JG. The neurophysiology of micturition; a clinical study of 550 patients. J Urol 1982;127:958–63.
- Skehan AM, Downie JW, Awad SA. The pathophysiology of contractile activity in the chronic decentralized feline bladder. J Urol 1993;149:1156–64.
- 25 Snape J, Duffin HM, Castleden CM. Urodynamic findings in sacrococcygeal chordoma. Br J Urol 1987;59:50–2.



Bladder dysfunction in Duchenne muscular dystrophy can be treated



en and boys with Duchenne muscular dystrophy may be suffering with bladder problems unnecessarily, a UK study has found. Symptoms of detrusor hyperreflexia, at least, can be treated successfully.

A chance finding of reported urinary problems in the condition alerted doctors at a paediatric neurology unit to a need to investigate further.

Please visit the Journal of Neurology, Neurosurgery, and Psychiatry website [www.jnnp. com] for a link to the full text of this article.

More than half (46/74) of 88 males aged 3–31 years with Duchenne muscular dystrophy at one neuromuscular clinic had urinary problems not previously raised with their doctors. These included daytime and night time incontinence, frequency, urgency, hesitancy, and stress incontinence and covered young boys able to walk and older males using wheelchairs. Twenty one males with symptoms were offered kidney and bladder ultrasonography before and after bladder emptying and videourodynamic tests to isolate the nature of the problem. Of the 10 who opted for both investigations, nine had results suggesting detrusor hyperreflexia; seven of them had a small bladder. Five with similar symptoms opted just for ultrasonography. The ultrasonographic studies confirmed complete emptying of the bladder in all patients. All reported symptoms improved significantly and night time incontinence resolved with oxybutinin treatment in 10 males (seven and three, respectively, from each group). The neurological reasons for the urinary symptoms were unclear.

Urinary problems are not generally recognised with Duchenne muscular dystrophy among doctors, and parents assume they are part and parcel of the condition.

▲ Archives of Disease in Childhood 2003;88:347-349.